Payment overview · 2025
General Payments
$1,346.22
59 reported records · 15 companies
Healthcare provider profile · identity verified
Gladys Torres, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MIAMI, FL · NPI 1396278867
Verified facts
What the public records show
CMS Open Payments records show Gladys Torres, ARNP received $1,346.22 in general payments during 2025 across 59 reported records.
PFIZER INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Nurtec Odt, Qulipta, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Qulipta by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuplazid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $281.64 | 20.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.90 | 19.2% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $181.10 | 13.4% | 10 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$128.94 | 9.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $114.05 | 8.5% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $110.27 | 8.2% | 5 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $55.25 | 4.1% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $41.92 | 3.1% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $34.45 | 2.6% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.00 | 2.1% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.65 | 2.0% | 1 | 2025 |
| BIOPROTECT MEDICAL, INC. | Unresolved — no canonical attribution shown | $26.56 | 2.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.37 | 1.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $21.40 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.72 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,346.22 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $295.15 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $281.64 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $198.52 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $191.48 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.84 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $110.27 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $60.38 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| BIOPROTECT BALLOON IMPLANT SYSTEM Normalized: bioprotect balloon implant system |
Device | BIOPROTECT MEDICAL, INC. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 350 | 157 |
| Duloxetine Hcl | Duloxetine Hcl | 242 | 123 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 241 | 123 |
| Baclofen | Baclofen | 110 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 103 | 68 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 102 | 52 |
| Rasagiline Mesylate | Rasagiline Mesylate | 92 | 53 |
| Naproxen | Naproxen | 90 | 46 |
| Levetiracetam | Levetiracetam | 80 | 24 |
| Donepezil Hcl | Donepezil Hcl | 71 | 39 |
| Rexulti | Brexpiprazole | 67 | 27 |
| Folic Acid | Folic Acid | 66 | 30 |
| Metoclopramide Hcl | Metoclopramide Hcl | 63 | 29 |
| Lidocaine | Lidocaine | 57 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | 22 |
| Meclizine Hcl | Meclizine Hcl | 50 | 22 |
| Lamotrigine | Lamotrigine | 47 | 11 |
| Trazodone Hcl | Trazodone Hcl | 44 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 27 |
| Divalproex Sodium | Divalproex Sodium | 41 | 12 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 41 | 18 |
| Risperidone | Risperidone | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Memantine Hcl Er | Memantine Hcl | 24 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | 11 |
| Qulipta | Atogepant | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | 14 |
| Topiramate | Topiramate | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Copaxone | Glatiramer Acetate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,346.22 · 59 records | PFIZER INC. | AMPYRA, AUSTEDO XR, Apokyn, BIOPROTECT BALLOON IMPLANT SYSTEM, CREXONT, INBRIJA, Motpoly XR, NUPLAZID, NURTEC ODT, QULIPTA, REXULTI, Radicava, SKYCLARYS, UBRELVY, VYALEV, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error